The insulin market is undergoing a significant shift as global drugmakers prioritize GLP-1 and new generation insulins. In response to this trend, Biocon, Wockhardt, and Eris have announced plans to double their insulin production capacities. Wockhardt’s Managing Director, Murtaza Khorakiwala, highlighted the company’s strategic positioning to seize the emerging opportunities in the insulin market, with […]